Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multidimensional analysis reveals distinct immune phenotypes and tertiary lymphoid structure-like aggregates in the bone marrow of pediatric acute myeloid leukemia.
Koedijk JB, van der Werf I, Penter L, Vermeulen MA, Barneh F, Perzolli A, Meesters-Ensing JI, Fiocco M, de Groot-Kruseman HA, Moeniralam R, Christensen KB, Porter B, Pfaff K, Garcia JS, Rodig SJ, Wu CJ, Hasle H, Nierkens S, Belderbos ME, Zwaan CM, Heidenreich O. Koedijk JB, et al. Among authors: heidenreich o. medRxiv [Preprint]. 2023 Oct 30:2023.03.03.23286485. doi: 10.1101/2023.03.03.23286485. medRxiv. 2023. PMID: 37961528 Free PMC article. Preprint.
Targeting pediatric cancers via T-cell recognition of the monomorphic MHC class I-related protein MR1.
Cornel AM, van der Sman L, van Dinter JT, Arrabito M, Dunnebach E, van Hoesel M, Kluiver TA, Lopes AP, Dautzenberg NMM, Dekker L, van Rijn JM, van den Beemt DAMH, Buhl JL, du Chatinier A, Barneh F, Lu Y, Lo Nigro L, Krippner-Heidenreich A, Sebestyén Z, Kuball J, Hulleman E, Drost J, van Heesch S, Heidenreich OT, Peng WC, Nierkens S. Cornel AM, et al. Among authors: heidenreich ot. J Immunother Cancer. 2024 Mar 21;12(3):e007538. doi: 10.1136/jitc-2023-007538. J Immunother Cancer. 2024. PMID: 38519054 Free PMC article.
Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1.
Coleman DJL, Keane P, Chin PS, Ames L, Kellaway S, Blair H, Khan N, Griffin J, Holmes E, Maytum A, Potluri S, Strate L, Koscielniak K, Raghavan M, Bushweller J, Heidenreich O, Rabbitts T, Cockerill PN, Bonifer C. Coleman DJL, et al. Among authors: heidenreich o. iScience. 2024 Mar 26;27(4):109576. doi: 10.1016/j.isci.2024.109576. eCollection 2024 Apr 19. iScience. 2024. PMID: 38638836 Free PMC article.
The MLL-Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML.
Rasouli M, Blair H, Troester S, Szoltysek K, Cameron R, Ashtiani M, Krippner-Heidenreich A, Grebien F, McGeehan G, Zwaan CM, Heidenreich O. Rasouli M, et al. Among authors: heidenreich o. Hemasphere. 2023 Jul 27;7(8):e935. doi: 10.1097/HS9.0000000000000935. eCollection 2023 Aug. Hemasphere. 2023. PMID: 37520776 Free PMC article.
Gene regulatory network analysis predicts cooperating transcription factor regulons required for FLT3-ITD+ AML growth.
Coleman DJL, Keane P, Luque-Martin R, Chin PS, Blair H, Ames L, Kellaway SG, Griffin J, Holmes E, Potluri S, Assi SA, Bushweller J, Heidenreich O, Cockerill PN, Bonifer C. Coleman DJL, et al. Among authors: heidenreich o. Cell Rep. 2023 Dec 26;42(12):113568. doi: 10.1016/j.celrep.2023.113568. Epub 2023 Dec 15. Cell Rep. 2023. PMID: 38104314 Free PMC article.
215 results